Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche/Maxygen Halt Development Of Next-Generation Pegasys Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

End of Roche relationship has no financial impact on Maxygen, which plans an update on unpartnered Phase II neutropenia candidate MAXY-G34 for early 2008, firm tells “The Pink Sheet” DAILY.

You may also be interested in...

Roche Polymerase Inhibitor Shows Promise In Phase II

Ahead of AASLD, Roche’s Senior Medical Director Thommes discusses the firm’s hepatitis C pipeline with “The Pink Sheet” DAILY.

Roche/Maxygen Early-Stage HCV/HBV Candidate Faces Setback

MAXY-alpha has been put on clinical hold based on Phase I observations.

Maxygen’s Neutropenia Candidate Shows Positive Results In Phase IIa Trial

Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts